| To: Mike McFarland who wrote (2543) | 6/30/2006 8:12:16 PM | | From: Ian@SI | | | | I have real time streaming Indices, quotes, charts, news.
I look at long term charts, moving averages, RSI, money flows and, especially, Rick's suggestions<G>.
I don't think I stand a chance against the professionals with their computer trading algorithms; so I tend to make real time decisions which may follow no precise formula. e.g. At this point, I have several naked put positions outstanding. So my recent trading tends toward building a cash cushion to protect against an early assignment.
Have a good weekend,
Ian |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Ian@SI who wrote (2544) | 7/1/2006 1:00:13 PM | | From: tuck | | | | TRCA was up over 20% Friday. If it's news, it's being priced in pretty slowly, as last news was Monday, and the big moves were Wednesday and Friday. Don't really follow it, but I understand the stock had been whacked recently on loosing some sort of ground to Insmed, which makes a similar product for the same population.
Say, Ian, I know of at least one other trade of yours that's going well so far. Good going! I, too, loaded a bit of biotech recently, and a bit too early. Chiefly AMGN, PDLI, ARNA, ENCY (my best timed purchase of the lot). Other positions that had calls written against them no longer do. Summer rally, please, for more than two days, this time? Pretty please, sugar on top?
Cheers, Tuck |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: tuck who wrote (2545) | 7/1/2006 3:01:13 PM | | From: hmpa | | | | TRCA was up over 20% Friday
This seems to be a part of a "very" unusual pattern for Russell additions and exclusions. Unlike any of the previous years I am aware of, most of the dumped issues went up in a meaningful way (e.g. see ISTA), while additions somewhat slumped, see e.g. finance.yahoo.com
I don't understand why it could have happened - other than for some reason accumulated short and long positions, respectively, in anticipation of the rebalancing were bigger than actual demand for shares.
(Alternative is if there is a large net short position on Russell ETF - I have no clue how it is getting processed - does ETF have to go and short the shares?) |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: hmpa who wrote (2546) | 7/1/2006 8:19:24 PM | | From: Ian@SI | | | | | I think the hedge funds from time to time get carried away with their attempts to steal nickles and dimes. The volume at the close on Friday was absolutely unreal both Nas and NYSE going over 3B shares. |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: tuck who wrote (2545) | 7/1/2006 8:27:54 PM | | From: Ian@SI | | | | Hi Tuck,
1. I see you caught my disease. ...the stock had been whacked recently on loosing some sort of ground to Insmed... Thank god that a well educated, literate sort can also suffer a momentary lapse.
2. I know of at least one other trade of yours that's going well so far. Yes, the NKTR play caught me by surprise. I really wasn't expecting much to happen before the end of July. It does make me wonder if I should just take the offering and hope to get it again prior to month end???
I haven't any clue whether the last couple days is the start of something serious; or, if it was just some technical Month/Quarter/Half move. |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Ian@SI who wrote (2548) | 7/1/2006 9:44:58 PM | | From: Robohogs | | | | I feel like an idiot myself - took losses in DOVP/NBIX complex, did not sell the expensive calls in SEPR to cover and only picked up small trading stakes in NKTR/ARNA. ARNA is up as much as NKTR after being down 8% right before FED moved - had thought about adding more but could not do so when Rick was ranting about the shorts as I was worried about the FED reaction. How stupid can one believe. Nice trades guys!
Ian - you are the only other NKTR owner I have seen post. Most are dismissive of them as "me-too" and lifestyle. I personally do not care as I think the valuation disconnect between them and AMLN is too large. Economics an Exubera are not quite as good as Byetta (20% royalty with some mfg costs offsetting vs half of profits) but I think Exubera will be a quicker hitter than many think. Of course, I want to be out when the lung problems start.
Jon |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Robohogs who wrote (2549) | 7/1/2006 10:00:52 PM | | From: Ian@SI | | | | | As Tuck said, IF pt compliance improves with Exubera, then it will be prescribed. I don't understand the needle phobia thing, but then again, I don't stick myself multiple times a day. |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: nigel bates | 7/5/2006 10:43:41 AM | | | | | | ARDM 30% on partnership 'restructuring' -
HAYWARD, CA--(MARKET WIRE)--Jul 5, 2006 -- Aradigm Corporation (Nasdaq:ARDM - News) today announced the execution of an agreement further developing the strategic partnership with Novo Nordisk. The agreement is designed to strengthen Novo Nordisk's patent position within the area of inhaled insulin as related products progress towards commercialization and has resulted in a non-dilutive cash infusion to Aradigm of $27.5 million. The Novo Nordisk inhaled insulin program is currently in Phase 3 clinical trials. This agreement is comprised of an intellectual property assignment, a royalty prepayment and an eight-year promissory note. The promissory note is secured by the royalty payments on the AERx Diabetes Management System (iDMS) sold under the Aradigm license.
The key features to the restructuring and cash infusion include:
-- Aradigm's receipt of $12 million in exchange for transferring to Novo
Nordisk the ownership of a select number of patents that are especially
important for inhaled insulin. Aradigm will retain exclusive, royalty-free
control of these patents outside the field of glucose control and will
continue to be entitled to royalties in respect to any inhaled insulin
products marketed by Novo Nordisk.
-- The receipt by Aradigm of $8 million in exchange for a 100 basis point
or 1% reduction on its average royalty rate set forth by the commercialized
AERx iDMS product. This will result in Aradigm receiving royalty rates that
will rise to an average of 5% or higher by the fifth year after
commercialization.
-- Finally, Novo Nordisk has paid Aradigm $7.5 million in a 5%, eight-
year note that is payable in three equal payments commencing in six years,
and is secured by the royalty payments to Aradigm upon the
commercialization of the AERx iDMS product. |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Ian@SI who wrote (2542) | 7/11/2006 2:36:06 PM | | From: scaram(o)uche | | | | Nah, I didn't catch anything at the end of the quarter. Did a little buying, but the only trading that I did was a couple of small winners to make up, in part, for losses held in the same issue.
Best, all!
Rick |
| | biotech fireworks | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
